Everolimus

• Everolimus is an mTOR inhibitor that modulates cell growth and division.
• It is primarily used for certain advanced cancers, such as kidney cancer, breast cancer, and neuroendocrine tumors, as well as for preventing organ rejection in transplant patients.
• The medication works by blocking a protein called mTOR, which is vital for cell proliferation and survival.
• Common side effects include mouth sores, fatigue, rash, and elevated blood sugar or cholesterol levels.
• Important drug information includes careful monitoring for adverse effects and potential interactions with other medications.

What is Everolimus and Its Mechanism of Action

Everolimus is an immunosuppressant and anticancer drug that functions as a mammalian target of rapamycin (mTOR) inhibitor. This medication is derived from sirolimus and works by forming a complex with the intracellular protein FKBP-12, which then binds to and inhibits mTOR. The inhibition of mTOR is central to how Everolimus works, as mTOR is a critical regulatory kinase involved in various cellular processes, including cell growth, proliferation, protein synthesis, and angiogenesis (the formation of new blood vessels).

By disrupting the mTOR pathway, Everolimus effectively slows down cell division and reduces the growth of cancer cells. In the context of organ transplantation, this mechanism helps to suppress the immune system’s response, thereby preventing the rejection of the transplanted organ. This dual action underscores its versatility in both oncology and transplant medicine, making it a valuable therapeutic agent.

What is Everolimus Used For?

Everolimus is a versatile medication approved for several distinct medical conditions, primarily in oncology and transplant medicine. The specific applications for what Everolimus is used for include:

• Advanced Renal Cell Carcinoma (RCC): It is used in patients whose disease has progressed on or after treatment with vascular endothelial growth factor (VEGF) targeted therapy.
• Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer: In combination with exemestane, it is used in postmenopausal women with advanced breast cancer after failure of treatment with letrozole or anastrozole.
• Progressive Neuroendocrine Tumors (NET) of Pancreatic Origin: For patients with unresectable, locally advanced or metastatic progressive disease.
• Subependymal Giant Cell Astrocytoma (SEGA) associated with Tuberous Sclerosis Complex (TSC): For patients requiring therapeutic intervention but not amenable to surgical resection.
• Renal Angiomyolipoma associated with TSC: For patients at risk of complications suchor hemorrhage or loss of kidney function.
• Prophylaxis of Organ Rejection: In adult heart or kidney transplant recipients at risk of immunological complications.

These diverse indications highlight Everolimus’s broad impact, leveraging its ability to modulate cell growth and immune responses.

Everolimus Side Effects and Important Drug Information

Like all medications, Everolimus can cause side effects, ranging from mild to severe. Understanding potential Everolimus side effects is crucial for patients and healthcare providers. Common side effects often include stomatitis (mouth sores), fatigue, rash, diarrhea, and infections. Metabolic changes such as elevated blood sugar (hyperglycemia) and increased cholesterol levels (hypercholesterolemia) are also frequently observed. More serious but less common side effects can include pneumonitis (inflammation of the lungs), kidney problems, and an increased risk of serious infections due to immunosuppression.

Important Everolimus drug information emphasizes the need for careful patient monitoring throughout treatment. Blood tests are regularly performed to check kidney function, liver function, blood cell counts, and drug levels to ensure the medication is within a therapeutic range and to detect potential adverse effects early. Patients should avoid grapefruit and grapefruit juice, as these can increase Everolimus levels in the blood, potentially leading to increased side effects. Live vaccines should also be avoided during treatment. It is essential for patients to report any new or worsening symptoms to their healthcare provider immediately. According to the World Health Organization (WHO), adverse drug reactions are a significant public health concern, underscoring the importance of comprehensive drug information and patient education for medications like Everolimus.